Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase

Cancer Science

Volumn 103, Issue 3, 2012, Pages 448-454

  Domoto, Takahiro ^a   Takino, Takahisa ^a   Guo, Luyang ^a   Sato, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; INTERSTITIAL COLLAGENASE; MATRIPTASE; MEMBRANE PROTEIN; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE; LEUKOCYTE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE 14; SPINT1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; METABOLISM; NEOPLASM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MATRIX METALLOPROTEINASE 14; NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SERINE ENDOPEPTIDASES;

EID: 84859701895     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02162.x     Document Type: Article

References (43)

1. Oberst MD, Johnson MD, Dickson RB et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002; 8: 1101-7.
2. Szabo R, Hobson JP, List K, Molinolo A, Lin CY, Bugge TH. Potent inhibition and global co-localization implicate the transmembrane kunitz-type serine protease inhibitor hai-2 in the regulation of epithelial matriptase activity. J Biol Chem 2008; 283: 29495-504.
3. Oberst MD, Anders J, Xie B et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001; 158: 1301-11.
4. Kataoka H, Suganuma T, Shimomura T et al. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999; 47: 673-82.
5. Szabo R, Molinolo A, List K, Bugge TH. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 2007; 26: 1546-56.
6. Shimomura T, Denda K, Kitamura A et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 6370-6.
7. Kim MG, Chen C, Lyu MS et al. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999; 49: 420-8.
8. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237-42.
9. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999; 274: 18231-6.
10. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological, processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999; 96: 11054-61.
11. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 2001; 22: 104-14.
12. Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006; 63: 2968-78.
13. List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol Med 2006; 12: 1-7.
14. Netzel-Arnett S, Hooper JD, Szabo R et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003; 22: 237-58.
15. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-5.
16. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of proteaseactivated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
17. Suzuki M, Kobayashi H, Kanayama N et al. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 2004; 279: 14899-908.
18. Kang JY, Dolled-Filhart M, Ocal IT et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63: 1101-5.
19. Shimomura T, Denda K, Kawaguchi T, Matsumoto K, Miyazawa K, Kitamura N. Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. J Biochem 1999; 126: 821-8.
20. Kataoka H, Shimomura T, Kawaguchi T et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40453-62.
21. Seiki M. Membrane-type matrix metalloproteinases. APMIS 1999; 107: 137-43.
22. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
23. Holmbeck K, Bianco P, Yamada S, Birkedal-Hansen H. MT1-MMP: a tethered collagenase. J Cell Physiol 2004; 200: 11-9.
24. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
25. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003; 94: 569-74.
26. Sato H, Takino T, Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005; 96: 212-7.
27. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
28. Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem 2002; 383: 1059-66.
29. Nishida Y, Miyamori H, Thompson EW, Takino T, Endo Y, Sato H. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type-1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2. Cancer Res 2008; 68: 9096-104.
30. Niiya D, Egawa N, Sakamoto T et al. Identification and characterization of Lutheran blood group glycoprotein as a new substrate of membrane-type 1 matrix metalloproteinase 1 (MT1-MMP): a systemic whole cell analysis of MT1-MMP-associating proteins in A431 cells. J Biol Chem 2009; 284: 27360-9.
31. Miyamori H, Takino T, Kobayashi Y et al. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 2001; 276: 28204-11.
32. Sakr MA, Takino T, Domoto T et al. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci 2010; 101: 2368-74.
33. Ahmad M, Takino T, Miyamori H, Yoshizaki T, Furukawa M, Sato H. Cleavage of amyloid-b precursor protein (APP) by membrane-type matrix metalloproteinases. J Biochem 2006; 139: 517-26.
34. Jin X, Yagi M, Akiyama N et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 2006; 97: 1327-34.
35. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 1996; 393: 101-4.
36. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 2003; 278: 26773-9.
37. Oberst MD, Chen LY, Kiyomiya K et al. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 2005; 289: 462-70.
38. Kudo T, Takino T, Miyamori H, Thompson EW, Sato H. Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci 2007; 98: 563-8.
39. Désilets A, Béliveau F, Vandal G, McDuff FO, Lavigne P, Leduc R. Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease. J Biol Chem 2008; 283: 10535-42.
40. Miyake Y, Tsuzuki S, Fushiki T, Inouye K. Matriptase does not require hepatocyte growth factor activator inhibitor type-1 for activation in an epithelial cell expression model. Biosci Biotechnol Biochem 2010; 74: 848-50.
41. Ovaere P, Lippens S, Vandenabeele P, Wim Declercq W. The emerging roles of serine protease cascades in the epidermis. Cell 2009; 34: 453-63.
42. Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res 2009; 69: 1828-35.
43. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 2003; 22: 223-36.